Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

The Ventana TROP2 RxDx Device, a computational pathology CDx, received FDA breakthrough designation for non–small cell lung cancer. AI-based image analysis in the device offers superior diagnostic ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes but increases treatment-related toxicity. Up-front stereotactic radiosurgery ...

Zongertinib showed a 71% overall response rate and 93% disease control rate in HER2-mutated NSCLC patients, with a median PFS of 12.4 months. No cases of interstitial lung disease were reported ...

Each year, 50,000 new lung cancer cases are diagnosed in France, with non–small cell lung cancer (NSCLC) accounting for 80% of these cases. More than two thirds of lung tumors are diagnosed at ...

Prior to HARMONi-6, there were no known Phase III clinical trials in NSCLC which have shown a statistically significant improvement compared to PD-(L)1 inhibitor therapy in combination with ...

Johnson & Johnson (J&J) has announced that an injectable version of Rybrevant (amivantamab) has been approved by the European Commission (EC) for two advanced non-small cell lung cancer (NSCLC) ...